Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
ECOR vs COCP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
COCP Captures Overall Composite Edge (45.4 HOLD vs 56.8 HOLD), While ECOR Leads 4–0 on Growth & Valuation Pillars
COCP Overall Winner
6-Pillar Tally: ECOR 4 – 0 COCP (2 Tie)
Matrix Metrics: ECOR 3 – 5 COCP
As of Nov 19, 2026, Cocrystal Pharma, Inc. (COCP) captures the overall head-to-head institutional edge over electroCore, Inc. (ECOR) on higher Unified Composite conviction (45.4/100 HOLD vs. 56.8/100 HOLD) after splitting the core matrix 5–3 (led by composite factor balance), while ECOR wins 4–0 across the 6-pillar growth and valuation breakdown. ECOR trades at $4.85 (N/M Forward P/E, -33.1% operating margin) versus COCP at $0.97 (N/M Forward P/E, -2646.0% operating margin).
- Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. COCP 45.4/100 HOLD), COCP captures the overall institutional head-to-head verdict (5–3 matrix metrics and 0–4 across the 6 pillars) due to superior fundamental profitability (-2646.0% vs. -33.1% operating margin) and revenue trajectory (+26.9% vs. +11.5% YoY).
- Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile COCP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ECOR vs COCP
ECOR
electroCore, Inc. Common Stock
$4.85
-6.19% 1D
Market Cap
$47.7M
TTM Revenue
$38M
Forward P/E
N/M
Beta / 30D Vol
1.52β · 155% Vol
Unified Composite Score
56.8
HOLD
Tech 68.0
Fund 53.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
COCP
Head-to-Head Winner
Cocrystal Pharma, Inc. Common Stock
$0.97
-0.72% 1D
Market Cap
$18.5M
TTM Revenue
$435,000
Forward P/E
N/M
Beta / 30D Vol
1.01β · 55% Vol
Unified Composite Score
45.4
HOLD
Tech 44.0
Fund 50.0
Flow 50.0
Mom 54.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ECOR 4 – 0 COCP)
1. Valuation Multiples
ECOR
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
1.4x
35.0x
2. Growth & Scale
ECOR
Revenue Growth (YoY)
+11.5%
+26.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$38M
$435,000
Market Cap
$47.7M
$18.5M
3. Profitability & Quality
ECOR
Gross Margin
87.7%
N/A
Operating Margin
-33.1%
-2646.0%
Net Profit Margin
-33.5%
0.0%
Return on Equity (ROE)
-478.7%
-219.1%
4. Balance Sheet & Cash Flow
ECOR
Cash Generation (TTM)
-$6.9M
-$7.6M
Cash Flow Margin
-18.1%
N/A
Net Cash / Leverage
$4.6M Net Debt
$3.3M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ECOR (3) vs COCP (5)| Institutional Metric | ECOR | COCP | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $47.7M | $18.5M | ECOR | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +11.5% | +26.9% | COCP | |
| Operating Margin (TTM) | -33.1% | -2646.0% | ECOR | |
| Net Profit Margin | -33.5% | 0.0% | COCP | |
| Return on Equity (ROE) | -478.7% | -219.1% | COCP | |
| 52-Week Range Position | 6% ($4–$13) | 16% ($1–$2) | COCP | |
| Beta / 30D Volatility | 1.52β · 155% Vol | 1.01β · 55% Vol | COCP | |
| Unified Institutional Score | 56.8 / 100 (HOLD) | 45.4 / 100 (HOLD) | ECOR | |
| Trailing 12M Revenue (USD) | $38M | $435,000 | Scale | |
| Gross Profit Margin (TTM) | 87.7% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.4x EV/Rev | N/M PEG · 35.0x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$6.9M ($4.6M Net Debt) | -$7.6M ($3.3M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
COCP +36.8 pp
3M Horizon
COCP +38.24 pp
6M Horizon
COCP +4.86 pp
1Y Horizon
ECOR +0.95 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ECOR Revenue | COCP Revenue | ECOR Op. Margin | COCP Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -5494.1% | N/A | ECOR |
| FY2019 | $0M | $10M | -1928.2% | -737.4% | COCP |
| FY2020 | $0M | $0M | -707.9% | -476.0% | COCP |
| FY2021 | $10M | N/A | -367.7% | N/A | ECOR |
| FY2022 | $10M | N/A | -266.2% | N/A | ECOR |
| FY2023 | $20M | N/A | -120.2% | N/A | ECOR |
| FY2024 | $30M | N/A | -48.3% | N/A | ECOR |
| FY2025 | $30M | N/A | -41.1% | N/A | ECOR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ECOR
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ECOR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
COCP
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ECOR Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
COCP Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ECOR vs COCP Key Questions & Quantitative Answers
As of Nov 19, 2026, Cocrystal Pharma, Inc. (COCP) captures the overall head-to-head institutional edge over electroCore, Inc. (ECOR) on higher Unified Composite conviction (45.4/100 HOLD vs. 56.8/100 HOLD) after splitting the core matrix 5–3 (led by composite factor balance), while ECOR wins 4–0 across the 6-pillar growth and valuation breakdown. ECOR trades at $4.85 (N/M Forward P/E, -33.1% operating margin) versus COCP at $0.97 (N/M Forward P/E, -2646.0% operating margin). Composite vs. Pillar Nuance: While ECOR currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. COCP 45.4/100 HOLD), COCP captures the overall institutional head-to-head verdict (5–3 matrix metrics and 0–4 across the 6 pillars) due to superior fundamental profitability (-2646.0% vs. -33.1% operating margin) and revenue trajectory (+26.9% vs. +11.5% YoY). Technical & Structure Timing Caution: ECOR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.5); meanwhile COCP is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ECOR leads the Growth & Scale pillar: ECOR posts +11.5% YoY revenue growth and +0.0% YoY earnings growth on $38M TTM revenue (87.7% gross margin, -33.1% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $435,000 TTM revenue (N/A gross margin, -2646.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ECOR cumulative revenue shifted +200.0% while COCP shifted N/A. In operating R&D and SG&A reinvestment, ECOR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.
ECOR screens cheaper on headline valuation multiples. ECOR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.4x EV/Revenue (-18.1% FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 35.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECOR (-478.7% ROE) versus COCP (-219.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ECOR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.52β · 155% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.01β · 55% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
COCP vs ECOR · Reverse Pair
ECOR vs PRPO
· Sector Peer
COCP vs PRPO
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal